Top Regulatory News Stories – Week Ending June 14, 2019

Genentech’s blood cancer drug Polivy earned an accelerated approval from the U.S. FDA due to the complete response rate shown during clinical trials. The FDA approved Merk’s Keytruda as a frontline treatment for head and neck cancer.  Keytruda was initially approved in 2014 for advanced melanoma and has since received approvals as treatment for[…]